

**Supplementary Table S2.** Distribution of the previous treatments (before the *ESR1* mutation detection) in the subgroup of patients with ER+ *ESR1*+ disease *versus* the patients with ER+ *ESR1*- disease.

	<i>ESR1</i> + (# patients)	<i>ESR1</i> - (# patients)
<b>Patients (total #)</b>	11	46
<b>Previous chemotherapies</b>	11 (100%)	31 (67%)
<b>Previous fulvestrant-containing regimens</b>	6 (54%)	20 (43%)
<b>Previous AIs ± targeted therapy</b>	8 (73%)	27 (59%)